GLP-1 Side Effects: A Complete Guide to What You Can Expect

You’ve heard about the dreaded GLP-1 side effects: hair loss, “Ozempic face,” even thyroid cancer. These medications can give you back years of health, but like any drug, side effects are part of the package and sometimes they’re tough to handle. 

In studies of people with type 2 diabetes, side effects were the number one reason for stopping treatment, which can feel discouraging if you are just starting out.^[1]

While most side effects of GLP-1 medications are mild and short lived, it’s important to know what you’re getting into all the same.

---

GLP-1 Side Effects at a Glance

• Nausea & vomiting
• Constipation
• Diarrhea
• Reflux & sulfur burps
• Loss of muscle and lean mass
• Skin, hair, and nail changes
• Fatigue, depression, and “the blahs”
• Dehydration

Less Common but Serious Side Effects

• Pancreatitis and pancreatic cancer
• Gallstones & gallbladder disease
• Thyroid cancer
• Acute kidney injury
• Retinopathy, macular degeneration, and nonarteritic anterior ischemic optic neuropathy (NAION)

---

Common GLP-1 Side Effects and How to Manage Them

Most side effects show up early, often within the first few days of beginning GLP-1 treatment. The good news is that these are usually mild and short-lived, often improving as your body adjusts. Knowing what to expect and how to respond can make treatment much easier and help you stay on track.

Nausea and Vomiting

Nausea is by far the most common side effect people experience when beginning GLP-1s.^[2] Studies show that more than half of people feel it at some point, usually when first starting the medication or after a dose increase.^[3] It is typically mild, but in rare cases it can progress to vomiting, which raises the risk of dehydration and kidney injury.^[4]

Fortunately, both nausea and vomiting usually respond to the same management strategies.

How to Manage Nausea

• Slow dose titration. Doctors emphasize not increasing the dose too quickly. Dose increases should only happen when nausea is mild or has mostly resolved.

• Eat smaller, more frequent meals. GLP-1s slow down digestion, so big meals can sit heavy in the stomach and trigger nausea. Spacing food out into four to six smaller meals instead of three large ones helps reduce that burden and keeps digestion moving more comfortably.

• Limit greasy, heavy, or spicy foods. These are harder to digest and may intensify nausea.

• Stay hydrated. Dehydration raises nausea risk and can cause other issues, so make fluids a priority.

• Consider switching medications. If you are on semaglutide and are experiencing severe nausea, your provider may consider switching you to tirzepatide (Zepbound®, Mounjaro®), which has a GIP component that can reduce nausea.^[5]

• Try anti-nausea drugs. Over-the-counter or prescription medications like Zofran® (ondansetron) or Reglan® (metoclopramide) can be used in stubborn cases, but only under the guidance of your healthcare provider.

For most people, nausea improves within a few weeks and can be managed without stopping treatment. However, if vomiting persists, reach out to your healthcare provider to prevent dehydration, and they may recommend IV fluids or other measures to avoid complications. Fortunately, this is not the typical experience for most patients.

---

Constipation

Constipation is another common side effect that, unlike nausea, often persists throughout treatment.^[2] In severe cases, it can lead to complications, such as bezoars, hardened masses in the stomach that sometimes require surgical removal.^[6] 

The good news is that this worst-case scenario is extremely rare, and with the right habits, constipation can usually be prevented or kept under control.

How to Manage Constipation

• Hydrate. Drink plenty of fluids, aiming for urine that is light yellow to clear.

• Eat a fiber-rich diet. Include whole, unprocessed foods like lentils, beans, fruits, and vegetables to keep things moving.

• Get physical activity. Regular exercise helps stimulate the bowels and reduce constipation.

• Take fiber supplements. Supplements like psyllium husk can help. However, they should be used under your provider’s guidance, since too much fiber can sometimes worsen constipation or cause bloating.

• Use laxatives with care. Options such as Miralax® (polyethylene glycol) or magnesium citrate can be used if needed with direction from your healthcare provider.

While constipation can be an ongoing challenge with GLP-1s, most people find that simple habits like hydration, fiber, and movement are enough to keep it under control.

---

Diarrhea

Diarrhea is less common than constipation but still affects 5%–25% of patients, most often in the first few weeks of therapy.^[2] It usually lasts only a few days, and while it often resolves on its own, it can still be uncomfortable and disruptive if not addressed.

How to Manage Diarrhea

• Adjust your diet. Avoid fatty foods, which can worsen symptoms, and consider adding soluble fiber (like oats or bananas) to bulk up stools.

• Stay hydrated. Replace lost fluids with water or electrolyte drinks to prevent dehydration.

• Try over-the-counter relief. Medications like Pepto-Bismol® (bismuth subsalicylate) or Imodium® (loperamide) can be used short term under your provider’s direction.

• Beware of medication interactions. Ask your healthcare provider to check for drug interactions. Diarrhea may be worse in people taking metformin, especially with omeprazole, and in some cases lowering the metformin dose can help.

• Explore probiotics. These can help restore a healthy balance of gut bacteria, which may make stools more solid and less frequent.^[7] They’re usually safe to try, but they don’t work for everyone.

Diarrhea is usually short lived and manageable, and with the small changes listed above it rarely becomes a long-term problem. However, if it persists, contact your healthcare provider, since ongoing diarrhea can cause dehydration and lead to other complications.

---

Reflux & Sulfur Burps

Reflux is one of the more common side effects of GLP-1 medications, often coming right after nausea and constipation.^[8][9] It happens because these drugs slow down how quickly food leaves the stomach. When food sits longer, there’s a higher chance of it refluxing back into the esophagus, which can cause heartburn, bloating, or a sour taste.

Patients with a history of reflux should be especially mindful when starting a GLP-1. Unlike nausea, which usually improves with time, reflux can linger for some people if not managed.

How to Manage Reflux

• Eat smaller meals. Sitting upright after eating and avoiding lying down right away can make a big difference.

• Watch food triggers. Heavy, greasy foods like pizza, wings, burgers, fries, and chips often make reflux worse.

• Boost digestion. Stay active, drink enough fluids, and add whole-food fiber like beans, lentils, fruits, and vegetables to support healthy digestion.

• Try simple relief. Antacids such as Tums® can help short-term. If symptoms continue, ask your provider about medications like Pepcid® (famotidine) or Prilosec® (omeprazole).

• Plan ahead for procedures. Studies show GLP-1s can increase stomach contents, but they haven’t clearly been linked to more aspiration during surgery. Guidelines on stopping before procedures vary, so talk with your care team.

Reflux can be uncomfortable, but for most people it’s manageable. With diet adjustments, lifestyle changes, and occasional medication, it rarely needs to stop treatment.

---

Muscle and Lean Mass Loss

When people lose weight, they lose both fat and fat-free mass.^[10] Fat-free mass includes muscle, bone, organs, and water. Some muscle loss is normal during weight loss, but the goal is to keep as much strength and function as possible. 

With GLP-1 medications, research is still ongoing to understand how much weight comes from fat compared to fat-free mass. Some lean mass loss is expected, but it doesn’t mean muscle is being lost in a dangerous way.

How to Protect Muscle and Strength

• Avoid rapid weight loss. I know, weight loss is the whole point of some GLP-1s. But losing more than 1.5%–2% of body weight per week raises the risk of muscle and bone loss.

• Lift heavy things. Resistance exercise is the most effective way to preserve muscle. Even light weights, resistance bands, or body-weight workouts help.

• Eat enough protein. Protein supports muscle retention, but exercise has a much bigger impact.

• Reframe progress. Even if some lean mass is lost, reduced body weight often makes daily activities easier, like walking, climbing stairs, or doing pull-ups.

With the right habits, GLP-1 weight loss can leave you stronger and more capable, not weaker.

---

Skin, Hair, and Nail Changes

GLP-1 medications can cause changes in the skin and hair.^[11] The most common issues are redness or itching at the injection site. Rarely, people may develop hives or immune-related skin conditions that require stopping the drug. 

Cosmetic effects like “Ozempic face” (a thinner, gaunt appearance from rapid fat loss in the face) and temporary hair shedding have also been reported. Hair loss is usually due to rapid weight loss or low nutrition, though some reports suggest a possible link between GLP-1s and alopecia. 

But at the same time, research shows GLP-1s may improve wound healing, reduce psoriasis inflammation, and potentially help other skin conditions.

How to Manage Skin and Hair Changes

• Report reactions. Tell your provider if you notice new rashes, hives, or blisters.

• Support hair health. Eat enough protein and vitamins to reduce shedding risk.

• Be patient with cosmetic changes. Many improve naturally over time as weight stabilizes.

• Stay informed. Ask your provider about emerging research on GLP-1 benefits for skin health.

Most skin and hair effects are mild, temporary, and manageable. With the right support, they rarely interfere with ongoing treatment.

---

Fatigue, Depression, and “The Blahs”

Some people on GLP-1s report a tired, flat, or unmotivated feeling.^[12] It can show up as fatigue, less interest in hobbies, or a general “blah” mood. Researchers believe this may be linked to dopamine pathways that affect both energy and pleasure.

How to Manage “The Blahs”

• Adjust the dose. Lowering the dose often improves both energy and mood without losing the benefits.

• Prioritize nutrition. Make sure you’re eating enough protein, calories, and balanced meals. Undereating can worsen fatigue and mood changes.

• Stay active. Light to moderate activity, even just walking or stretching, can improve both energy and mental well-being.

• Talk to your provider. If fatigue or flat mood lingers, your doctor may suggest medication support such as bupropion (Wellbutrin®).

• Don’t ignore warning signs. If you feel persistently down, numb, or lose interest in life, bring it up quickly with your provider.

For many people, these symptoms improve over time as the body adjusts. When managed early, the Blahs don’t need to derail treatment.

---

Dehydration

Dehydration with GLP-1 medications usually happens because of nausea, vomiting, or diarrhea. If fluid loss is severe, you may feel dizzy, weak, or notice darker urine.^[13] Most cases are mild, but untreated dehydration can stress the kidneys and cause bigger problems.^[4]

Most dehydration issues happen in the first few weeks after starting or increasing your dose, since this is when nausea and vomiting are usually the strongest.

How to Prevent and Manage Dehydration

• Drink consistently. Sip water through the day instead of drinking large amounts all at once.

• Check urine color. Aim for very light yellow or clear.

• Replace electrolytes. Use electrolyte drinks if you’re sweating, vomiting, or having diarrhea.

• Titrate slowly. Raise your dose gradually to reduce digestive side effects.

• Adjust food choices. Avoid greasy or spicy foods that worsen nausea or vomiting.

• Know the warning signs. Dizziness, dark urine, fast heartbeat, or not peeing enough means you need more fluids and possibly medical help.

With steady fluid intake and slow dose changes, dehydration is usually easy to prevent and manage.

---

Less Common or Serious Side Effects: Addressing Concerns and Real Risks

Most people will never experience these complications, but it helps to know what they are. The real risks are often smaller than what you see online, and with good monitoring most are preventable.

Gallstones and Gallbladder Disease

Rapid weight loss, especially more than 1% of body weight per week, can increase the risk of gallstone formation by changing how bile is made and released.^[14] These stones may cause painful gallbladder attacks or even pancreatitis if they block the ducts.

Research in people with type 2 diabetes has found that GLP-1 users have a higher chance of gallbladder and bile duct problems compared with those on other diabetes medications. The risk is highest in the first six months of treatment and includes about twice the likelihood of needing gallbladder removal surgery.

How to Reduce the Risk

• Aim for gradual weight loss. Keep weight loss at about 0.5%–1% of body weight per week rather than losing too quickly.

• Know the warning signs. Right upper abdominal pain, nausea, or pain after fatty meals should be checked promptly.

• GLP-1s are still safe without a gallbladder. People who have had gallbladder removal can continue GLP-1 therapy.

Gallbladder problems are uncommon but important to monitor. With gradual weight loss and attention to warning signs, most patients can continue treatment safely.

---

Pancreatitis and Pancreatic Cancer

Large clinical trials have not shown an increased risk of pancreatitis or pancreatic cancer with GLP-1 medications compared to placebo. However, pancreatitis can still occur, most often as a secondary complication when gallstones block the pancreatic duct.^[15]

Earlier reviews found some case reports during drug development and post-marketing surveillance. For example, a handful of cases were seen with exenatide and liraglutide, while none were reported for albiglutide or taspoglutide at the time. 

These reports raised concerns, but so far larger studies and FDA evaluations have not confirmed a clear increase in risk.

How to Reduce the Risk

• Watch for symptoms. Severe abdominal pain that radiates to the back, nausea, or vomiting should be evaluated right away.

• Manage gallstone risk. Because gallstones are a leading trigger of pancreatitis, gradual weight loss and awareness of gallbladder symptoms are important.

• Provider monitoring. Clinicians may monitor pancreatic enzymes or review risk factors if symptoms arise.

Pancreatitis is rare in people taking GLP-1s. Staying aware of warning signs and addressing gallbladder issues promptly are the best ways to minimize risk.

---

Thyroid Cancer

GLP-1 medications come with a black-box warning for medullary thyroid cancer (MTC). This warning is based on rodent studies where the drugs caused changes in thyroid cells.

In people, the picture looks different. Human thyroid C-cells have very few GLP-1 receptors, and large clinical trials have not shown an increased risk compared to placebo.

A newer nationwide study from France did find a possible link between GLP-1 use and thyroid cancer, especially MTC, in people treated for 1–3 years.^[16] But thyroid cancer is rare, and the study had some limits, so the results should be read with caution.

How to Reduce the Risk

• Genetic testing. Recommended for people with a family history of MTC or multiple endocrine neoplasia type 2 (MEN2).

• Stay vigilant. Report neck lumps, trouble swallowing, or hoarseness to your provider.

• Provider monitoring. Clinicians may check thyroid history and risk factors before starting therapy.

MTC is extremely rare, and most evidence shows no increase in risk with GLP-1s in humans. Still, anyone with a family history or other thyroid risk factors should be monitored more closely.

---

Acute kidney injury

GLP-1 medications do not usually damage the kidneys directly. Problems can occur if severe nausea, vomiting, or diarrhea cause dehydration.^[3] When the body loses too much fluid, the kidneys may not get enough blood flow, which can trigger acute kidney injury (AKI). 

This type of kidney issue is often reversible with rehydration and, if needed, stopping the drug. Rarely, immune-related inflammation of the kidneys (acute interstitial nephritis) has been reported.

How to Protect Kidney Health

• Pause the medication. If vomiting or diarrhea is persistent, stop your GLP-1 and contact your provider.

• Stay hydrated. Consistent fluid intake helps prevent kidney strain.

• Be cautious with other medications. Drugs like ACE inhibitors, ARBs, or NSAIDs can increase kidney stress when combined with dehydration.

• Seek care quickly. If you have reduced urination, swelling, or confusion, urgent evaluation may be needed.

Most kidney problems linked to GLP-1s are caused by dehydration and improve once fluids are replaced.

---

Retinopathy, Macular Degeneration, and NAION

GLP-1 medications may be linked to certain eye complications, mainly in people with diabetes who already have eye disease and experience rapid improvements in blood sugar. 

A 2023 meta-analysis of 93 clinical trials with more than 100,000 participants found a small increase in early-stage retinopathy and other retinal side effects compared with placebo.^[17] Yet, at the same time, GLP-1s appeared to protect against late-stage retinopathy when compared with insulin.

Possible Eye Conditions

• Diabetic retinopathy (DR). The primary concern, rapid drops in blood sugar from GLP-1 therapy can temporarily worsen existing DR, which is why it has been highlighted in research.

• Diabetic macular edema (DME). This eye condition is related to diabetic retinopathy. In some cases, it can get worse if blood sugar improves too quickly. There isn’t strong proof that GLP-1 medicines directly cause DME, but it’s something doctors keep an eye on.

• General vision changes. Some patients report blurred vision early in treatment. This is usually related to blood sugar shifts and often resolves once glucose stabilizes.

• Other ocular Issues. Rare case reports describe vitreous hemorrhage or retinal detachment, but these are inconsistent and usually tied to underlying diabetes, not the medication itself.

How to Reduce the Risk

• Eye exams. Schedule regular dilated eye exams, especially before and during treatment if you already have retinopathy.

• Blood sugar control. Avoid sudden, large drops in glucose by aiming for steady improvements. One way to do this is by eating balanced meals with protein, fiber, and healthy fats, which slow digestion and help keep blood sugar levels more stable. Skipping meals or eating mostly refined carbs can make swings worse.

• Report vision changes. Blurred vision, new floaters, or sudden vision loss should always be checked by a doctor. These symptoms are often nothing serious, but because eye complications can occur with diabetes and GLP-1 therapy, it’s important not to ignore them.

Most people taking GLP-1s do not develop new or worsening eye problems. With regular monitoring and gradual diabetes management, the risk of serious complications remains low.

---

Long-Term Side Effects

GLP-1 medications have been in use for almost 20 years, beginning with exenatide in 2005. Since then, they have been tested in hundreds of clinical trials and used by millions of people worldwide. 

What to know

• Most side effects appear early in treatment and usually improve as your body adjusts to the dose.
• Most common long-term side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation.
• Less common risks include gallbladder disease and, in rare cases, pancreatitis.
• Thyroid C-cell tumors have been seen in rodents but have not been confirmed in humans.
• GLP-1s can become less effective over time. 
• Stopping treatment often leads to weight regain or higher blood sugars.

Long-term studies show that GLP-1 medications remain safe and effective.^[18] No new safety issues have been found, and research suggests they may even help protect the heart and kidneys.

---

Safety, Strategy, and Next Steps

Many of the side effects on this list are rare. However, according to data nausea, vomiting, diarrhea, and constipation affect 40%–70% of patients on GLP-1 medications. The good news is most side effects improve with time, and simple strategies can make them easier to handle.

The FDA advises against their use in people with a personal or family history of medullary thyroid carcinoma (MTC), in those with Multiple Endocrine Neoplasia type 2 (MEN2), or in patients with severe gastroparesis or past serious allergic reactions.

That said, GLP-1s are not bad for most people. They are typically safe and effective. Be sure to review your full health history with your provider before starting and talk openly about side effects during treatment so you can get the support you need.

With the right approach, the benefits of GLP-1 medications often far outweigh the risks.

Ready to take the next step? If you’re interested in starting GLP-1 treatment, our guides can help you find trustworthy care and make confident decisions about your health.

Find the Right GLP-1 for You

---

FAQs

---

Sources

1. Sikirica, M. V., Martin, A. A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017). Reasons for discontinuation of GLP1 receptor agonists: Data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 10, 403–412. https://doi.org/10.2147/DMSO.S141235
2. Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., Garcia-de-Lucas, M. D., Núñez, J., Obaya, J. C., José Soler, M., Luis Górriz, J., & Rubio-Herrera, M. Á. (2022). Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: A multidisciplinary expert consensus. Journal of Clinical Medicine, 12(1), 145. https://doi.org/10.3390/jcm12010145
3. Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2015). Adverse effects of GLP-1 receptor agonists. The Review of Diabetic Studies: RDS, 11(3), 202. https://doi.org/10.1900/RDS.2014.11.202
4. Roncal-Jimenez, C., Lanaspa, M. A., Jensen, T., Sanchez-Lozada, L. G., & Johnson, R. J. (2015). Mechanisms by which dehydration may lead to chronic kidney disease. Annals of Nutrition and Metabolism, 66(Suppl. 3), 10–13. https://doi.org/10.1159/000381239
5. Hayes, M. R., Borner, T., & De Jonghe, B. C. (2021). The role of GIP in the regulation of GLP-1 satiety and nausea. Diabetes, 70(9), 1956–1961. https://doi.org/10.2337/dbi21-0004
6. Preda, V., Khoo, S. S. Y., Preda, T., & Lord, R. V. (2023). Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonists: potential relevance for bariatric and other gastric surgery. BJS Open, 7(1), zrac169. https://doi.org/10.1093/bjsopen/zrac169
7. Bodke, H., Jogdand, S., & Jogdand, S. D. (2022). Role of probiotics in human health. Cureus, 14(11). https://doi.org/10.7759/cureus.31313
8. Chang, M. G., Ripoll, J. G., Lopez, E., Krishnan, K., & Bittner, E. A. (2024). A scoping review of GLP-1 receptor agonists: Are they associated with increased gastric contents, regurgitation, and aspiration events? Journal of Clinical Medicine, 13(21), 6336. https://doi.org/10.3390/jcm13216336
9. Gregory, F. A. (2025). Living well on Ozempic, Mounjaro, and Wegovy: A practical guide to managing nausea, constipation, and lifestyle changes on GLP-1 medications. Jstone Publishing. 
10. Tinsley, G. M., & Heymsfield, S. B. (2024). Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments. Journal of the Endocrine Society, 8(11), bvae164. https://doi.org/10.1210/jendso/bvae164
11. Burke, O. M., Sa, B., Cespedes, D. A., & Tosti, A. (2025). Dermatologic implications of glucagon-like peptide-1 receptor agonist medications. Skin Appendage Disorders. https://doi.org/10.1159/000544023
12. Yapici-Esper, H., Appadurai, V., Eren, C. Y., Yazici, D., Pizzagalli, D. A., Werge, T., & Hall, M.-H. (2020). Association between GLP-1 receptor gene polymorphisms with reward learning, anhedonia and depression diagnosis. Acta Neuropsychiatrica, 32, 218–225. https://doi.org/10.1017/neu.2020.14
13. He, L., Li, Q., Yang, Y., Li, J., Luo, W., Huang, Y., & Zhong, X. (2024). Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. Frontiers in Pharmacology, 15, 1416985. https://doi.org/10.3389/fphar.2024.1416985
14. Faillie, J. L., Oriana, H. Y., Yin, H., Hillaire-Buys, D., Barkun, A., & Azoulay, L. (2016). Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Internal Medicine, 176(10), 1474–1481. https://doi.org/10.1001/jamainternmed.2016.1531
15. Anderson, S. L., & Trujillo, J. M. (2010). Association of pancreatitis with glucagon-like peptide-1 agonist use. Annals of Pharmacotherapy, 44(5), 904–909. https://doi.org/10.1345/aph.1M676
16. Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J. L. (2023). GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care, 46(2), 384–390. https://doi.org/10.2337/dc22-1148
17. Kapoor, I., Sarvepalli, S. M., D’Alessio, D., Grewal, D. S., & Hadziahmetovic, M. (2023). GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Survey of Ophthalmology, 68(6), 1071–1083. https://doi.org/10.1016/j.survophthal.2023.07.002
18. Hemmer, A., Maiter, D., Buysschaert, M., & Preumont, V. (2019). Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: a retrospective real-life study in 131 patients. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13(1), 332–336. https://doi.org/10.1016/j.dsx.2018.09.007